Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

ClinicalTrials.gov ID: NCT07282613

Public ClinicalTrials.gov record NCT07282613. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The study will last for about 1 year and 3 months.

Study identification

NCT ID
NCT07282613
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
80 participants

Conditions and interventions

Eligibility (public fields only)

Age range
10 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2026
Primary completion
Sep 6, 2029
Completion
Mar 29, 2030
Last update posted
Sep 8, 2026

2026 – 2030

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Yale School of Medicine New Haven Connecticut 06511 Not yet recruiting
Encore Medical Research Boynton Beach Boynton Beach Florida 33436 Recruiting
Nemours Chld Clnc Jacksonville Jacksonville Florida 32207 Recruiting
Innovus Clinical Kissimmee Florida 34741 Recruiting
D&H National Research Centers Tamarac Florida 33321 Recruiting
Clinical Research Trials of Florida Tampa Florida 33607 Recruiting
Columbus Research Foundation Columbus Georgia 31904 Recruiting
Eastside Bariatric and Gen Surg Snellville Georgia 30078 Recruiting
SIU Medicine Springfield Illinois 62702 Not yet recruiting
Riley Hospital For Children Indianapolis Indiana 46202 Not yet recruiting
University of Iowa Iowa City Iowa 52242 Recruiting
Great Lakes Research Inst. Southfield Michigan 48075 Recruiting
UBMD Pediatrics Buffalo New York 14203 Not yet recruiting
NYU Langone Orthopedic Center New York New York 10016 Not yet recruiting
Children's Hosptl Philadelphia Philadelphia Pennsylvania 19104 Not yet recruiting
Monument Health Clinical Rsrch Rapid City South Dakota 57701 Not yet recruiting
LifeDoc Health Memphis Tennessee 38115 Recruiting
Amir Ali Hassan, MD, PA Houston Texas 77089 Recruiting
Consano Clinical Research, LLC Shavano Park Texas 78231 Recruiting
UVA Health Systems Charlottesville Virginia 22903 Recruiting
Seattle Children's Research Institute Seattle Washington 98105 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07282613, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2026 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07282613 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →